Structural insights into drug development strategy targeting EGFR T790M/C797S

Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation. Though WZ4002/CO-1686/AZD9291 are effective in overcoming EGFR T790...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Zhu, Su-Jie, Zhao, Peng, Yang, Jiao, Ma, Rui, Yan, Xiao-E, Yang, Sheng-Yong, Yang, Jing-Wen, Yun, Cai-Hong
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2018
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5862605/
https://ncbi.nlm.nih.gov/pubmed/29568384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24113
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires